Jill M. Quigley was appointed Director of Filana Therapeutics, Inc. As of November 14, 2026, Filana Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on November 12, 2026, naming 1 appointment (Form 8-K, November 12, 2026).
FILANA THERAPEUTICS, INC. named a new Director on Nov 12. 29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Filana Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Filana Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-11-12. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Filana Therapeutics, Inc. files it.
Layoffs on record: about 10 jobs, latest 2025-01-07 (layoff filings and notices).
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-12 | In | Director | 8-K, 2026-11-12 |
Selling to them or working with them? See who runs Filana Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Watch Filana Therapeutics, Inc.
Get an email when Filana Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Filana Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Filana Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Filana Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Who leads Filana Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Jill M. Quigley, appointed (filed 2026-11-12).
New leaders reset buying decisions — get the Full Report on Filana Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Filana Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Filana Therapeutics, Inc.Every change, in the filing's words
Appointed: Jill M. Quigley, Director
Ms. Quigley was appointed as a Class I director and will serve with a term expiring at the Company's 2028 annual meeting of stockholders.
- : Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (d) Appointment of Class I Director On and effective November 8, 2026, the Board of Directors ("Board") of Filana Therapeutics, Inc. (the "Company") appointed Jill M. Quigley to the Board.
- Ms. Quigley has not been appointed to any committees of the Board.
Tools for this story
Each opens in a new tab, filled in for Filana Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
